2019 Maher Award Presentation - Dr. Goldstein

Event

2019 Maher Award Presentation - Dr. Goldstein

Event Date/Time: 
February 5, 2020 - 4:00pm to 5:00pm
Location: 
Building E, Lecture Hall E1
Description: 
<br>Dr. Robert Goldstein, recipient of the 2019 Maher Award, will present a brief presentation entitled,&nbsp;<i>“Hemodynamic Effects of Late Sodium Current Inhibitors in a Swine Model of Heart Failure”,&nbsp;</i>on Tuesday, February 4, 2020, at 0800, in Lecture Room E1.&nbsp; There will be time for questions at the end of the presentation.<br><br><p><b>ABSTRACT</b></p><p>Objectives: To evaluate possible treatment-related hemodynamic changes, we administered ranolazine or mexiletine to swine with heart failure (HF) and to controls.</p><p>Background: Ranolazine and mexiletine potently inhibit depolarizing late Na+ current (INa,late) and Na+ entry into cardiomyocytes. Blocking Na+ entry may increase forward-mode Na/Ca exchange and reduce cellular Ca+2 load, further compromising systolic contraction during HF.</p><p>Methods and Results: Anesthetized tachypaced HF swine received ranolazine (n = 9) or mexiletine (n = 7) as boluses, then as infusions; the same experiments were performed in 10 nonpaced controls. The swine with HF had characteristic elevated left ventricular end-diastolic pressure (LVEDP) and reduced maximal left ventricular pressure rise (+dP/dtmax) and left ventricular peak systolic pressure (LVSP). No significant change occurred after ranolazine dosing for any parameter: LVEDP, +dP/dtmax, LVSP, heart rate, maximal LV pressure fall rate (dP/dtmax), or time constant for isovolumic relaxation. Similar results seen in additional swine with HF: 7 were given mexiletine, and 7 others were given ranolazine after a 27% rate decrement to maximize INa,late. Patch-clamped HF cardiomyocytes confirmed drug-induced INa,late blockade.</p><p>Conclusions: Ranolazine or mexiletine blocking INa,late neither worsened nor improved hemodynamics during advanced HF. Although results must be clinically confirmed, they suggest inhibition of INa,late by ranolazine or mexiletine may not exacerbate HF in patients. (J Cardiac Fail 2019;25:828-36)</p><p>Key Words: Ranolazine, mexiletine, systolic dysfunction, action potential.</p><p><i>[The full article can be found at: PMID: 31461671 DOI: 10.1016/j.cardfail.2019.08.<wbr>015]</i></p>